个体化治疗软件对乳腺癌术后辅助化疗有效性的验证研究

中国医药导报 2011 年4月 第8卷 第10期

杂志级别：中国科技核心期刊；第一作者：南京医科大学 姜勇；文章类型：论著；

[摘要] 目的：通过回顾性的生存期分析研究，来验证黄新恩博士开发的乳腺癌个体化治疗软件的临床实用价值。方法：研究对象为在江苏省肿瘤医院行乳腺癌切除术，术后病理确诊为乳腺癌并接受术后辅助化疗的患者。入组患者被分为3组；A组：实际治疗方案与软件预测完全相同。B组：实际治疗方案与软件预测部分相同。C组：实际治疗方案与软件预测完全不同。通过比较A、B、C组生存期，来验证乳腺癌个体化治疗软件的有效性。结果：从1992年12月～2007年7月，310例女性乳腺癌患者随机入组本项研究。A、B、C组患者数目分别为112、106、89例。通过绘制生存曲线，进行生存分析，结果发现A组与B组（P=0.0004）、A组与C组（P=0.0046）生存期差异均有统计学意义。A组患者预后分别优于B组和C组。结论：本研究研究证实乳腺癌个体化治疗软件能够对乳腺癌患者术后辅助化疗提供很有价值的临床指导，具用良好的实际应用价值，值得推广应用。

[关键词] 乳腺癌；医学软件；术后化疗；生存期

A validation study on efficacy of individualized treatment software for breast cancer patients who received postoperative adjuvant chemotherapy

[Abstract] Objective: To validate the clinical value of an individualized treatment software which developed by Doctor HUANG Xin′en. Methods: Patients with histologically confirmed breast cancer after mastectomy who received postoperative chemotherapy in Jiangsu Cancer Hospital were recruited in this study. All eligible patients were divided into three groups, group A, regimen of practical chemotherapy was consistent with software predication; group B, partly consistent with software predication; group C, inconsistent with software predication. Overall survival (OS) were compared among group A、B and C to determine the efficacy of individualized treatment software. Results: From November 1992 to July 2007, 310 female breast cancer patients were recruited into this study. Numbers of patients in group A, B, and C are 112, 106 and 89 respectively. The survival curves between group A and B (P=0.000 4), and group A and C (P=0.004 6) were significantly different, with prognosis of group A better than both group B and C. Conclusion: Our validation study confirms that individualized treatment software could provide important information on adjuvant chemotherapy for postoperative breast cancer patients, with strong clinical value.

Key words: Breast cancer; Medical software; Postoperative chemotherapy; Overall survival